Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment?
Authors:
- 10 May 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 19 (9) , 907-918
Abstract
Introduction: Treatment goals for IBD patients traditionally focused on symptom control. It is increasingly recognized that many patients have continued disease activity without symptoms. Subclinical inflammation increases the risk of disease flares and long-term complications. A consensus is therefore emerging on the need to treat beyond symptoms and to define clear treatment targets for IBD patients receiving biologic medicines. Areas covered: We review validated tools used in IBD for monitoring clinical and endoscopic response to therapy. We discuss the value of using non-invasive tests in assessing disease activity. We summarise the latest guidelines in IBD treatment and review recommendations regarding therapeutic drug monitoring. We examine the role of monitoring for and prevention of avoidable complications of treatment. Expert Opinion: The goals of treatment in IBD are to achieve both clinical remission and mucosal healing. Whether we adopt a top-down or more conventional treatment strategy there is now an imperative to monitor patients using a combination of endoscopic and biochemical markers to assess the degree of continuing inflammation and establish early disease control. TDM has facilitated huge improvement in the ability to personalize delivery of biologics. This has allowed for early detection and prevention of loss of response.Keywords
Funding Information
- provided
This publication has 84 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH StudyAmerican Journal of Gastroenterology, 2013
- Article Commentary: Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs)Health Services Insights, 2013
- Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)Gut, 2011
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical TrialsClinical Therapeutics, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseaseGastrointestinal Endoscopy, 2006